SEMA3B基因在肺癌组织中的表达及其与p53表达、肿瘤血管新生的关系  

Expression of SEMA3B mRNA and its correlation with protein p53 expression and angiogenesis in human lung carcinoma

作　　者：赵俊[1] 杨炯[1] 赵杨[1] 王亮朝[1] 赵澜涛[2] 

机构地区：[1]武汉大学人民医院呼吸内科,武汉430060 [2]武汉大学人民医院心胸外科,武汉430060

出　　处：《肿瘤》2006年第9期842-846,共5页Tumor

摘　　要：目的:研究抑癌基因SEMA3B(semaphorin 3B)在肺癌组织中表达的临床意义及其与p53表达、肿瘤血管新生的关系。方法:利用RT-PCR检测46例肺癌及远癌正常肺组织中SEMA3BmRNA和VEGF165mRNA表达,免疫组化SP法检测p53蛋白表达和微血管密度(MVD)。结果:肺癌组织中SEMA3BmRNA表达缺失率显著高于正常肺组织(47.8%vs0%,P<0.01),其表达异常与肺癌组织分化程度、淋巴结转移和临床病理分期有关,而与性别、年龄和组织分型无关;肺癌组织中SEMA3BmRNA表达与VEGF165mRNA、p53蛋白表达及MVD均呈显著负相关(P<0.05)。结论:SEMA3B基因在肺癌组织中表达下调,并与肿瘤细胞凋亡、血管新生有密切关系,提示其表达异常对肺癌的发生、发展及预后起重要作用。Objective：To investigate the expression and clinical significance of tumor suppressor gene SEMA3B （semaphorin 3B）, and its correlation with p53 protein expression and angiogenesis in human lung carcinoma. Methods： Forty six cases of human lung carcinoma and paired 46 cases of noncancerous tissues were collected. Reverse transcription polymerase chain reaction （RT-PCR） was applied to examine the SEMA3B mRNA and vascular endothelium growth factor VEGF165 mRNA expression. Immunohistochemical SP method was used to determine the protein expression of p53 and microvessel density （MVD）. Results： In lung carcinoma, loss expression of SEMA3B mRNA was significantly higher than those of normal lung tissue （47.8% vs 0%, P〈0.01 ）. The abnormal expression of SEMA3B mRNA significantly correlated with cell differentiation, lymph node metastasis, and clinicopathological staging, but not with gender, age, and histological classification. The expression of SEMA3B mRNA was negatively related to the expression of VEGF165 mRNA, p53 protein and MVD in lung carcinoma （P〈0.05）. Conclusion： Loss or abnormal down regulation of the expression of SEMA3B gene is a frequent event in lung oncogenesis, and it is highly correlated with tumor cell apoptosis and angiogenesis, which might play an important role in the malignant genesis, progression and prognosis of lung carcinoma.

关 键 词：肺肿瘤 信号素3B 蛋白质P53 血管内皮生长因子类 肿瘤形成过程 血管形成调节剂 

分 类 号：R735.1[医药卫生—肿瘤]